



**Therapeutic Strategies for  
Cardiovascular-Kidney Metabolic Syndrome:**  
Addressing the Interwoven Triad of Heart Failure,  
Chronic Kidney Disease, and Diabetes

22nd World Congress Insulin Resistance Diabetes & Cardiovascular Disease  
Pre-Congress Breakfast CME Symposium  
**Thursday, December 12, 2024 | 7:00 AM - 8:00 AM**

This activity is provided by



This activity is supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company.

# Faculty



**Jay H Shubrook, DO,  
FACOFP, FAAFP**  
Professor Primary Care Dept  
Diabetologist  
Touro University California  
College of Osteopathic  
Medicine  
Vallejo, CA, USA



**Jennifer B Green, MD**  
Professor of Medicine  
Division of Endocrinology  
Duke Clinical Research Institute  
Duke University School of  
Medicine  
Durham, NC, USA



**Pam R Taub, MD,  
FACC, FASPC**  
Professor of Medicine  
Director of Preventive Cardiology  
Founder and Director of Step  
Family Cardiac Rehabilitation and  
Wellness Center  
University of California, San Diego  
La Jolla, CA, USA



**Matthew R Weir, MD**  
Professor and Chief  
Division of Nephrology  
Department of Medicine  
University of Maryland School  
of Medicine  
Baltimore, MD, USA

# Activity Overview



## Target Audience

This activity is intended for primary care physicians and other members of the multidisciplinary, interprofessional healthcare team in the U.S who care for patients with cardio-renal metabolic disease.

## Educational Objectives

After completing this activity, the participant should be better able to:

- Describe the complex interplay between CKD, HF, and T2D in the context of CKM syndrome.
- Analyze the epidemiological trends and pathophysiological mechanisms underlying the interconnectedness of HF, CKD, and T2D, and their implications for patient prognosis and quality of life.
- Evaluate the current evidence base supporting emerging therapeutic strategies, including sodium-glucose cotransporter 2 (SGLT2) inhibitors and aldosterone synthase inhibitors (ASIs), for managing CKM syndrome, with a focus on their potential to mitigate morbidity and mortality.
- Formulate evidence-based treatment plans for patients with CKM syndrome that consider the complex interactions between HF, CKD, and T2D to enhance patient quality of life.

## Agenda

- Introduction & Housekeeping
- Exploring the Connections Between CKD, HF, and T2D
- Unveiling Epidemiological Trends and Pathophysiological Links
- Emerging Therapeutic Strategies for CKM syndrome
- Tailoring Treatment for CKM syndrome
- Q&A with Expert Faculty
- Post-Test, Evaluation & Claim Your Credit

# Part 1

Exploring the Connections Between CKD, HF, and T2D


Educational Objective: Describe the complex interplay between CKD, HF, and T2D in the context of CKM syndrome.

# Setting The Stage: What We Already Know




Cardiovascular-kidney-metabolic (CKM) syndrome is a health disorder that occurs due to connections among heart disease, kidney disease, diabetes, and obesity.

CKM leads to poor health outcomes.



# CVD in Patients With or Without CKD



AMI, acute myocardial infarction; CHF, congestive heart failure; CKD, chronic kidney disease; CVA, cerebrovascular accident; CVD, cardiovascular disease; TIA, transient ischemic attack.

House AA. *Am J Kidney Dis.* 2018;72(2):284-295.

# Stages of CKM Syndrome

Learning Point!

**Stage 0:  
No Risk Factors**



A focus on primordial prevention and preserving cardiovascular health


**Stage 1:  
Excess/Dysfunctional Adipose Tissue**



Overweight/obesity  
Abdominal obesity  
Impaired glucose tolerance


Nonmetabolic etiologies of hypertension

**Stage 2:  
Metabolic Risk Factors and CKD**



Nonmetabolic etiologies of CKD


**Stage 3:  
Subclinical CVD in CKM Syndrome**



**Risk equivalents of subclinical CVD in CKM Stage 3:**

- Very high-risk CKD (G stage 4 and 5 CKD or by KDIGO heat map)
- High predicted risk for CVD using risk calculator

**Stage 4: Clinical CVD in CKM Syndrome**



Afib, atrial fibrillation; ASCVD, atherosclerotic cardiovascular disease; CHD, coronary heart disease; KDIGO, Kidney Disease Improving Global Outcomes; PAD, peripheral artery disease.

Ndumele CE, et al. *Circulation*. 2023;148(20):1606-1635.


# Part 2

## Epidemiological Trends and Pathophysiological Links

Educational Objective: Analyze the epidemiological trends and pathophysiological mechanisms underlying the interconnectedness of HF, CKD, and T2D, and their implications for patient prognosis and quality of life.



# Pathophysiology





MASLD, metabolic dysfunction-associated steatotic liver disease.

Marassi M, Fadini GP. *Cardiovasc Diabetol.* 2023;22(1):195.

# Association of eGFR and Risk of Death and CV Events



Large integrated health system including 1,120,295 patients who had serum creatinine measured between 1996 and 2000 and median follow-up of 2.84



eGFR, estimated glomerular filtration rate; PY, person/patient years.

Go AS, et al. *N Engl J Med.* 2004;351:1296-1305.

# Role of Mineralocorticoid Receptor Activation



Heightened MR activity plus inappropriate MR activation ultimately lead to increased myocardial stiffness, left ventricular hypertrophy, and the development of glomerular and interstitial fibrosis in the kidneys.

MR, mineralocorticoid receptor.


Buonafine M, et al. *Am J Hypertens*. 2018;31(11):1165-1174; Jia G, et al. *Biochim Biophys Acta Mol Basis Dis*. 2017;1863(8):2012-2018; Lothar A, Hein L. *Hypertension*. 2016;68(1):6-10; Mihai S, et al. *J Immunol Res*. 2018;2018:2180373.

# Part 3

## Emerging Therapeutic Strategies for CKM syndrome

Educational Objective: Evaluate the current evidence base supporting emerging therapeutic strategies, including sodium-glucose cotransporter 2 (SGLT2) inhibitors and aldosterone synthase inhibitors (ASIs), for managing CKM syndrome, with a focus on their potential to mitigate morbidity and mortality.

# KDIGO: Comprehensive Treatment Approach



ASCVD, atherosclerotic cardiovascular disease; BP, blood pressure; CCB, calcium channel blocker; CKD, chronic kidney disease; CKD-MBD, Chronic kidney disease-mineral and bone disorder; GLP-1 RA, Glucagon-like peptide-1 receptor agonists; HTN, hypertension; ns-MRA, Non-steroidal mineralocorticoid receptor antagonists; PCSK9i, Proprotein convertase subtilisin/kexin type 9 inhibitor; RAS, renin-angiotensin system; SGLT2i, sodium-glucose cotransporter 2 inhibitors; T1D, type 1 diabetes, T2D, type 2 diabetes.

# Four Pillars of Care CKM



Modified from Blazek O, Bakris GL. *Am Heart J Plus*.


GLP-1, Glucagon-like peptide-1; MR, mineralocorticoid receptor antagonist; RAS, Renin-angiotensin system; SGLT2, sodium-glucose cotransporter 2.

Copyright © 2024 Medical Learning Institute

# Four Pillars of Care



Learning Point!



# Novel Approaches in CKM Syndrome



**RAAS:** Pivotal in regulating BP and fluid-electrolyte balance, aldosterone synthesis is a crucial step

**ASIs:** Novel approach to modulating aldosterone, with potential advantages over MRAs in HTN and its complications, including CKD

**Baxdrostat** (CIN-107): Shown promise in treating treatment-resistant HTN

- Phase 3 trials underway, with a focus on uncontrolled HTN, CKD, and primary aldosteronism

**Lorundrostat:** Target-HTN: reduces systolic BP, especially in patients with suppressed plasma renin activity

- Lower doses showed significant BP reduction with fewer AEs

**Vicadrostat (BI 6905170):** Potent ASI in patients with CKD, aiming to address the AEs associated with RAAS inhibition

- Dose-dependent reductions in albuminuria
- Vicadrostat + empagliflozin: additive benefits, including kidney protection and reduced hyperkalemia



# Part 4

Tailoring Treatment for CKM Syndrome: Navigating Complex Interactions

Educational Objective: Formulate evidence-based treatment plans for patients with CKM syndrome that consider the complex interactions between HF, CKD, and T2D to enhance patient quality of life.

# Collaboration in CKM Syndrome Management



**“Cardiorenal disease is an important and potentially fatal complication in T2D, representing an unmet clinical need which should be considered when choosing future optimal preventive strategies in the management of these patients, adding a cardiorenal preventive approach to an already existing and quietly successful atherosclerotic preventive approach.”**